Pfizer Appoints Jeffrey Legos as New Chief Oncology Officer
Jeffrey Legos has been appointed as Pfizer's new Chief Oncology Officer, effective immediately57.
Legos joins Pfizer from Novartis, where he served as Executive Vice President and Global Head of Oncology and Hematology Development15.
In his new role, Legos will lead Pfizer's cancer R&D efforts, overseeing work from preclinical to late-stage clinical development5.
Legos brings over two decades of experience in leading pharmaceutical oncology teams, with a track record of more than 40 drug approvals6.
He replaces interim Chief Oncology Officer Roger Dansey, who is retiring5.
This appointment is part of a series of leadership changes at Pfizer following its $43 billion acquisition of Seagen in 20235.
Legos will report to Chris Boshoff, Pfizer's new R&D head and Chief Scientific Officer5.
Prior to his tenure at Novartis, Legos held various leadership positions at GlaxoSmithKline (GSK)15.
Legos holds a PhD in physiology from Temple University School of Medicine and an MBA in Finance from Villanova University School of Business1.
Sources:
1. https://medtechalert.com/people/jeff-legos/
5. https://www.fiercebiotech.com/biotech/pfizer-taps-ex-novartis-leader-helm-cancer-rd-work
6. https://endpts.com/pfizer-hires-novartis-oncology-exec-to-steer-its-cancer-ambitions/
7. https://www.biocentury.com/article/654998/novartis-jeffrey-legos-becomes-chief-of-oncology-at-pfizer